UK prescribing of antipsychotics for dementia patients shows sharp decline

16 July 2012

The percentage of dementia patients in England being prescribed antipsychotic drugs fell sharply over the last six years, says a new report from the Health and Social Care Information Centre (HSCIC). However, there was strong regional variation, with rates of prescribing of antipsychotic drugs up to six times higher in some areas of the country than in others.

The use of antipsychotic medication can lead to serious side effects for people with dementia. The first ever national primary care audit on the subject shows the percentage of dementia patients being prescribed antipsychotic drugs fell by 10 percentage points in the last six years – from 17% in 2006 to 7% in 2011.

Information from nearly 197,000 people with dementia from more than 3,800 practices in England was submitted to National Dementia and Antipsychotic Prescribing Audit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical